Challenge on Biomarkers and Treatment for Ovarian Cancer and Cervical Cancer

Guest Editor:

Dr. Kevin M. Elias
Director of the Gynecologic Oncology Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions:
closed (15 November 2022)

Message from the Guest Editor

Dear Colleagues,

Ovarian cancer is the leading cause of gynecologic cancer death in the United States and Europe, and cervical cancer is the leading cause of gynecologic cancer death worldwide. Biomarkers which can identify women at increased risk for these diseases or that may select individuals for targeted therapies are acutely needed. Tissue, circulating, and imaging markers are needed to triage patients into screening and therapeutic trials. This Special Issue will summarize current data concerning the following topics: early detection, prognostic biomarkers, and targeted therapies for ovarian and cervical cancer.

Dr. Kevin M. Elias
Guest Editor

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us